NUVB (Nuvation Bio Inc.) Stock Financials & Earnings | Market Cap Arena

NUVB (Nuvation Bio Inc.) Stock Financials & Earnings | Market Cap Arena

NUVBNuvation Bio Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NYSE

Revenue (TTM)$63M

Net Income (TTM)-$205M

EPS (TTM)-$0.60

Free Cash Flow (TTM)$0

Gross Margin86.6%

Op. Margin-338.7%

Net Margin-325.3%

FCF Margin0.0%

P/S Ratio (TTM)26.1x

P/E Ratio (TTM)—

YoY Rev Growth+699.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$27M
Q2 23	$0	$0	-$26M
Q3 23	$0	$0	-$26M
Q4 23	$0	$0	-$21M
Q1 24	$0	$0	-$20M
Q2 24	$1M	$88K	-$470M
Q3 24	$727K	-$788K	-$48M
Q4 24	$6M	$1M	-$54M
Q1 25	$3M	$990K	-$59M
Q2 25	$5M	$2M	-$64M
Q3 25	$13M	$10M	-$56M
Q4 25	$42M	$41M	-$34M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	1145.8x	—
Q3 24	760.5x	—
Q4 24	208.8x	—
Q1 25	150.1x	—
Q2 25	114.5x	—
Q3 25	61.5x	—
Q4 25	26.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$19M	-$19M
Q2 23	-$17M	-$18M
Q3 23	-$16M	-$16M
Q4 23	-$15M	-$15M
Q1 24	-$16M	-$16M
Q2 24	-$37M	-$37M
Q3 24	-$31M	-$31M
Q4 24	-$46M	-$46M
Q1 25	-$43M	-$43M
Q2 25	-$48M	-$48M
Q3 25	-$53M	-$53M
Q4 25	$144M	$144M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$12K
Q2 23	$22K
Q3 23	$22K
Q4 23	$13K
Q1 24	$27K
Q2 24	$0
Q3 24	$148K
Q4 24	$13K
Q1 25	$72K
Q2 25	$181K
Q3 25	$12K
Q4 25	$265K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	-5.9%
Q2 23	—	-31.0%
Q3 23	—	-10.2%
Q4 23	—	-14.4%
Q1 24	—	-23.8%
Q2 24	—	+1705.6%
Q3 24	—	+85.4%
Q4 24	—	+186.4%
Q1 25	—	+207.4%
Q2 25	+236.8%	-85.5%
Q3 25	+1704.7%	+42.4%
Q4 25	+633.1%	+27.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$5M	—
Q2 23	$6M	—
Q3 23	$5M	—
Q4 23	$4M	—
Q1 24	$5M	—
Q2 24	$10M	666.8%
Q3 24	$7M	1028.3%
Q4 24	$10M	178.4%
Q1 25	$8M	254.7%
Q2 25	$12M	248.9%
Q3 25	$8M	61.1%
Q4 25	-$28M	-66.7%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$19M	$8M	—	—
Q2 23	$19M	$8M	—	—
Q3 23	$19M	$8M	—	—
Q4 23	$15M	$5M	—	—
Q1 24	$13M	$7M	—	—
Q2 24	$454M	—	—	$16M
Q3 24	$28M	—	—	$20M
Q4 24	$29M	—	—	$26M
Q1 25	$25M	—	—	$35M
Q2 25	$27M	—	—	$38M
Q3 25	$29M	$37M	$500K	—
Q4 25	$34M	—	—	$40M

Revenue Segments

Quarter	License	Product
Q2 25	$4M	$1M

Revenue by Geography

Quarter	China	Japan	United States
Q3 24	$100K	$600K	—
Q1 25	$3M	$200K	—
Q2 25	$3M	$241K	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$30M	$617M	$647M
Q2 23	$50M	$581M	$631M
Q3 23	$24M	$595M	$619M
Q4 23	$43M	$569M	$611M
Q1 24	$35M	$562M	$597M
Q2 24	$34M	$543M	$577M
Q3 24	$30M	$519M	$549M
Q4 24	$36M	$467M	$503M
Q1 25	$48M	$414M	$462M
Q2 25	$248M	$360M	$608M
Q3 25	$99M	$450M	$549M
Q4 25	$164M	$365M	$529M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	219M	+0.1%
Q2 23	219M	+0.0%
Q3 23	219M	+0.0%
Q4 23	219M	-0.0%
Q1 24	219M	+0.1%
Q2 24	245M	+11.7%
Q3 24	274M	+11.8%
Q4 24	337M	+23.2%
Q1 25	339M	+0.5%
Q2 25	341M	+0.6%
Q3 25	342M	+0.5%
Q4 25	344M	+0.6%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$0	36
FY 21	$0	64
FY 22	$0	53
FY 23	$0	51
FY 24	$36K	220
FY 25	$63	1.0M